Active substance |
atezolizumab |
Holder |
Roche |
Status |
closed |
Indication |
adjuvant treatment following resection and platinum‐based chemotherapy for adult patients with stage IIB‐III non‐small cell lung cancer (NSCLC) whose tumours have PD‐L1 expression on ≥50% of tumour cells (AL43776). |
Public documents |
|
Approbation amendment | |
Last update |
11/08/2022 |
Tecentriq®
Last updated on 10/09/2024